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Surfactant substitution in the newborn by application of artificial surfactant
Colin John Morley
Department of Pediatrics, University of Cambridge, UK Surfactant treatment is given on the assumption that surfactant deficiency is the major cause of respiratory distress syndrome (RDS). However, we know that babies with RDS are also very immature. They have a number of interrelated problems which are difficult to separate from surfactant deficiency: difficulty clearing their lung fluid; their lung structure is very immature; they have a patent ductus arteriosus with relative pulmonary hypertension and pulmonary hyperperfusion; their muscle tone is poor and their ribs are soft; they have erratic respiratory control which is prone to apnoea; surfactant is present but in reduced amounts with poor physical properties and there is often a massive leak of protein on to the alveolar surface which interferes with the surfactant function. It is important to remember that surfactant is only one of these problems and therefore surfactant therapy cannot be expected to cure RDS although it may reduce the severity of some of the symptoms.
In 1977 we synthesized an artificial lung surfactant composed of dipalmitoylphosphatidylcholine and unsaturated phosphatidylglycerol, called ALEC standing for artificial lung expanding compound [1 -3, 6 ]. This has physical properties similar to natural surfactant when used in a crystalline state and applied to an air-water interface, in excess, at 37 °C. We initially tested this artificial surfactant by measuring the compliance of artificially ventilated 27 day fetal rabbits comparing the effect with untreated controls and animals treated with natural rabbit surfactant extract [8] (figure 1). After 30 minutes ventilation the compliance was higher in both treated groups than the controls but highest in the natural surfactant group. However, by 60 minutes both natural and artificial surfactant treated groups had similar values.
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Encouraged by this result, the physical properties of the surfactant and its lack of potentially toxic components, we started using the artificial surfactant in premature babies. This was used in a study between September 1979 and January 1982 as one 25 mg dose of powder given to resuscitated babies at birth down the endotracheal tube [5, 7] . It was a non-randomized, case controlled, study eventually involving 129 babies under 35 weeks gestation. The control babies had a mortality of 19% compared qith 4% of the surfactant treated babies. randomized controlled trial with 360 babies under 34 weeks gestation to study the prophylactic effect of ALEC suspension given at birth on respiratory support and compliance during the first few days of life. Babies were unselected and bora in one of the hospitals under 35 weeks gestation. They were randomized to surfactant or control just before birth. ALEC powder, 50 to 100 mgs was hand shaken with 1 ml saline at 4 °C just before delivery. Specimens were obtained for subsequent L/S ratio analysis. One ml of saline was the control substance. Surfactant or saline were placed in the pharynx at birth. If the baby was intubated further doses were given down the endotracheal tube at 10 minutes 1 hour and 24 hours. Trial treatment was not disclosed to the clinical teams. Compliance of the respiratory system was measured where possible at 1, 6, 24, 48 hours and 7 days. Randomized babies were excluded from the analysis if they were stillborn or had gross malformations. The trial was analyzed by treatment as randomized. The factors which influence the outcome of premature babies are shown in table I. Three hundred and forty-one unselected babies were entered into the trial. Fourteen were ineligible because they were stillborn or had major malformations. There were 163 surfactant treated and 164 controls, 69 were surfactant treated babies and 67 were controls were under 30 weeks gestation. The data for babies under 30 weeks gestation are shown separately or in brackets. The two groups are reasonably well matched.
In this trial there was no apparent effect from surfactant treatment in babies of 30 weeks gestation or more. This is because the incidence of RDS and its complications were very low, only 1% have an IVH, PDA or die. Two thirds are in oxygen for under 24 hours and 75% are not ventilated. Therefore the results shown are for the babies under 30 weeks gestation.
Compliance of the respiratory system was measured at the bedside using an oesophageal balloon for dynamic compliance or ventilator pressure for static compliance, and a pneumotachograph in an endotracheal tube or facemask. Figure 2 shows compliance measurements for babies under 30 There is little effect at 1 hour, but significant improvements in the surfactant treated group at 6 and 24 hours. At 48 hours and 7 days the compliance is higher but the difference is not significant. The compliance of the surfactant treated babies rose rapidly in the first 6 hours to a plateau whereas the controls improved slowly over the first few days. Figure 3 shows the inspired oxygen concentrations for the two groups of babies under 30 weeks gestation over the first 4 days of life. Note the scale on the bottom is not linear and the error bars are standard error of the mean. It is presented in this way to be comparable to the data of EN-HORNING [8] . It shows that from 6 hours the surfactant treated babies had inspired oxygen requirements significantly lower than the controls. hours the surfactant treated babies had peak inspiratory pressures significantly lower than the controls. Table II shows the incidence of complications for babies under 30 weeks gestation. They are patent •ductus arteriosus, pneumothorax, death at any time while in the neonatal intensive care unit, the need for oxygen therapy longer than 28 days, the use of paralyzing agents during ventilator therapy and peri ventricular hemorrhages. It shows the numbers in each group and the percentage of each complication with 95% confidence intervals for the difference between the two groups. There was no significant difference in the incidence of patent ductus arteriosus or pneumothorax. The mortality for the surfactant treated babies was significantly reduced from 34% to 19%. That is 15 less deaths per 100 babies. The 95% confidence interval is wide with a possible effect of a reduction of 1 death to 31 fewer deaths per 100 babies. When considering the incidence of all other complications it must be remembered that more surfactant treated babies survived to be at risk of the complication.
There was a significant reduction in the number of surfactant treated babies receiving prolonged oxygen therapy. This effect was equivalent to 18 less babies per 100 with 95% confidence intervals of 3 to 33 less receiving oxygen beyond 28 days.
The use of pancuronium was considered to be a complication of RDS because babies with the worst lung disease were paralyzed. The use of pancuronium in the surfactant treated babies was reduced from 52% to 27% a reduction of 25 per 100 babies with 95% confidence interval from 7 to 43 less babies being paralyzed. The incidence of all grades of periventricular hemorrhages was significantly reduced equivalent to 21 babies per 100 from 40% to 19% with confidence intervals showing a possible reduction from 6 less hemorrhages to 36 less hemorrhages per 100 babies. Data on mortality: Babies die from a variety of causes, not all RDS. Eighty eight per cent (21 out of 24) of the controls died as a consequence of RDS compared with only 50% (7 out of 14) of the surfactant treated babies (p <0.05), showing that the reduction in mortality was particularly affecting RDS deaths. Figure 5 shows the incidence of periventricular hemorrhages for Cambridge babies. Nottingham babies were not regularly scanned. It shows the number of babies with hemorrhages divided into subgroups. E is equivocal; 1 is germinal layer hemorrhage; 2 and 3 are hemorrhages contained within the ventricles; 4 is hemorrhage into the brain parenchyma and PM is parenchymal hemorrhage found at postmortem in babies who died before they could be scanned, the numbers of these are very small. The difference is significant overall and also for grade 4 hemorrhages separate- In May 1984 we started a second stage of this trial [9] . The purpose was to define the effect of artificial surfactant on the complications of prematurity in babies between 25 and 29 weeks gestation. Including babies of this gestation already randomized in the Cambridge-Nottingham trial approximately 300 babies were required to show a 25% reduction in mortality from 36% to 27% with a 75% power. This required collaboration from 10 British neonatal units to produce a quick result. The protocol for this trial was almost identical to the Cambridge Nottingham trial. Babies entered the study if they were born in hospital between 25 and 29 weeks gestation. They were randomized to surfactant or control just before birth. Randomization was stratified by gestational age to prevent imbalance. The strata were 25 and 26 weeks and 27, 28 and 29 weeks. Approximately 100 mg of surfactant powder suspended in 1 ml of cold saline or 1 ml of saline as the control substance were placed in the pharynx at birth. If the baby was intubated further doses were given down the endotracheal tube at 10 minutes 1 hour and 24 hours. The randomization and treatment were kept secrete. Babies were retrospectively excluded from the main analysis because they were stillborn, grossly malformed or not resuscitated. Analysis was for treatment groups as randomized.
Three hundred and twenty-eight babies were entered into the trial. There were 164 in each treatment group, 20 were ineligible. The factors which influence the outcome of premature babies are shown in table III. They are well matched between the groups particularly for birthweight, sex, labor, steroids and beta-adrenergic stimulants.
RDS is the major complication of prematurity. We developed a simple classification prior to the trial. It is based on the number of hours a baby receives more than 30% oxygen in the first 5 days. Babies receiving more than 30% oxygen for under 24 hours were defined as having no RDS. Babies receiving more than 30% oxygen for 25 to 48 hours had mild RDS. Babies in more than 30% oxygen for 2 to 5 days had moderate RDS and more than 5 days severe RDS. If a baby died in the first 5 days receiving more than 30% oxygen the RDS was graded severe. There are 159 surfactant treated babies and 149 controls. In the No RDS grade there were over one third more surfactant treated babies than controls. In the severe grade there were 29% fewer surfactant treated babies. There is little difference between the groups in the two intermediate grades. An analysis for trend is significant at the 3% level, showing the surfactant treated babies have less severe RDS. Table IV shows the effect on hours of ventilation in the first 10 days using multiple regression analysis. The first ten days were chosen as the time when prophylactic ALEC treatment might have most effect on respiration. Only survivors were included even though more controls died. This therefore gives a conservative analysis. The parameters taken into account were surfactant, sex, gestational age, first or subsequent multiple births and non-Cambridge centers. The baseline was a control, male, singleton at 25 weeks gestation born in Cambridge. Such a baby has an average of 183 hours ventilation in the first 10 days. The coefficients can be added or subtracted from this value to show the effect of each parameter. Surviving surfactant treated babies had on average 20 hours less ventilation in the first 10 days than the controls. This was significant at the 5% level. Table V shows the complications of prematurity in the two groups. They are: all deaths in the neonatal intensive care unit, deaths in the first 28 days of life, parenchymal brain hemorrhages detected ultrasonically, oxygen therapy for more than 10 days, pneumothorax or interstitial emphysema, and patent ductus arteriosus and infection. It shows the percentage for each treatment group with 95% confidence intervals for the difference in percentage points and the significance of that difference. The overall mortality for the surfactant treated babies was reduced from 30% of the controls to 19%, an 11% point difference with a 95% confidence interval from 2 to 21 fewer deaths per 100 babies. The 28 day mortality was reduced from 27% to 14% in the surfactant treated babies, a 13% point reduction with 95% confidence interval from 4 to 22 fewer deaths per 100 babies. When considering the incidence of all other complications it must be remembered that more of the surfactant treated babies have survived to be at risk of the complication. The incidence of parenchymal brain hemorrhages was reduced from 24% to 16% a reduction of 8 percentage points with 95% confidence interval of 1 more to 17 less hemorrhages per 100 babies. All babies are in- 1 Five ALEC treated babies and 6 controls were not scanned therefore only 154 ALEC babies and 143 controls are included. 2 As defined serious postnatal infection was after the first 24 hours, NEC does not occur in the first 24 hours. The denominator for these was 152 ALEC treated babies and 139 controls. 3 There were 138 ALEC treated babies and 117 controls surviving 10 days. 4 Pneumothorax here refers to pneumothorax and interstitial emphysema. eluded except for 5 surfactant treated and 6 controls who were not scanned. The incidence of other intraventricular and germinal layer hemorrhages was 19% in each group. Forty-three percent of surviving control babies received oxygen therapy for more than 10 days compared with 36% of surfactant treated babies. There was little difference in the incidence of pneumothoraces and interstitial emphysem, patent ductus arteriosus or infection.
We have now been studying the effect of artificial surfactant in premature babies under 35 weeks gestation since 1979. It has now been used at birth 12 large neonatal centers and 323 babies treated with 334 controls some randomized others not. The studies have consistently shown a reduced mortality. Overall there has been a significant reduction in mortality from 18.5% to 11% (p < 0.008).
In conclusion, this artificial surfactant when given prophylactically reduces the severity of the RDS, the hours of ventilation and high inspired oxygen concentrations, the incidence of parenchymal brain hemorrhages and most significantly the mortality. It dies not appear to have any major harmful side effects.
I have concentrated on my own artificial surfactant data. However, there are other studies using mixtures of phospholipids, particularly from Professor OPLADEN which show similar results, that is RDS is not cured but the major complications are reduced. It is interesting that the clinical results from artificial surfactant treatment show very similar results to natural surfactant treatment when given at birth. I hope that the good results from all the different studies will mean that in the near future the outlook for very premature babies will be improved.
Abstract
A protein-free artificial surfactant (ALEC) composed of two phospholipids when given as a prophylactic treatment at birth to very premature babies in randomized controlled trials. It was shown to reduce the severity of RDS, the ventilator pressure, the inspired oxygen requirements, the compliance of the respiratory system, the neonatal mortality and the incidence of ventricular hemorrhage. There are no apparent side effects from this treatment. 
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